Company
Twilight Bioscience illuminates new paths in neuroscience and oncology. We harness precision immunotherapy to target the root causes of ALS, other neurological disorders and cancer. Our mission is to develop effective treatments bringing a new dawn of hope to patients and families facing those devastating diseases.
Vaccines have been used for centuries to prevent diseases caused by external pathogens by inducing an immune response against them. However, many of the current health threats, such as cancer and neurodegenerative diseases, are not caused by external pathogens but by the abnormal expression of endogenous proteins. At Twilight Bioscience we have developed a vaccine technology able to precisely target pathological proteins preserving physiological functions.
Most neurodegenerative diseases are proteinopathies: disorders characterized by the accumulation of specific proteins within neurons or in the brain parenchyma. In cancer, abnormal expression of certain proteins triggers the immortalization of cells and the metastasis of tumors. Many of the current treatments for those diseases involve the use of monoclonal antibodies against the abnormally expressed proteins. However, their production is very costly, and their clinical application involve chronic treatment. At Twilight Bioscience we have developed a Fc-fusion vaccine platform, which induces high levels of polyclonal antibodies against precisely selected epitopes of pathogenic proteins, enabling a cost-effective treatment and prevention immunotherapy for neurological diseases and cancer.
Leadership
Rahul Bhansali
CBO & Co-founder
With over 14 years of experience in founding, scaling, and exiting innovative companies. His mission is to create positive impact in the world by proving that a human-centric, engineering-minded approach to venture building can unlock the world's most potent problem-solving potential; the way science makes it to market.
Ajay Verma MD, PhD
CEO & Co-founder
A translational leader with more than 30 years of experience advancing new therapies through preclinical and clinical development in Big Pharma and Biotech. He is a neurologist and pragmatic innovator devoted to the development of therapeutics and diagnostics.
Marta Garcia Montojo, PhD
Scientific Director
An accomplished and dynamic scientist with extensive expertise in neurodegeneration, virology and immunology. With over 20 years of experience in fundamental research and translational medicine in Academia and pharmaceutical companies, she is devoted to develop therapies to improve the quality of life of patients.
John Altin, PhD
Scientific Advisor
Professor of Neurology at Trinity College and Leader of the ALS National Clinical and Research Program. She is a renowned neurologist and ALS investigator.
Avi Nath, MD
Scientific Advisor
Clinical Director and Chief of the Section of Infections of the Nervous System (NINDS). He is a world leader in neurovirology research with seminal investigations in HIV and COVID. His work led to the discovery of HERV-K contribution to ALS pathology.
Colin Masters, MD
Scientific Advisor
Laureate Professor of Neuropathology at the University of Melbourne. He is a globally renowned, award-winning biomedical researcher who was the first to characterize amyloid proteins in Alzheimer’s disease.
Paul Maruff, PhD
Scientific Advisor
Chief Scientific Officer at Cognate and former Professor at Florey Institute of Neuroscience and Mental Health. He is a key opinion leader in Alzheimer’s Disease research.
